HUTCHMED Shares Are Trading Higher After the Company Announced That Its NDA for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma Was Accepted in China With Priority Review Status.
HUTCHMED股票上涨，该公司宣布其针对复发或难治性滤泡性淋巴瘤的Tazemetostat新药申请已在中国获得优先审评状态。
